Corticosteroid use for diabetic macular edema: old fad or new trend?

Current Diabetes Reports
Michael W Stewart

Abstract

Diabetic retinopathy is the leading cause of blindness in working age individuals in developed countries. Most cases of diabetes related vision loss result from breakdown of the blood-retinal barrier with resultant diabetic macular edema (DME). For over 30 years, laser photocoagulation has been the standard therapy for DME, but most eyes do not experience significant improvements in visual acuity. Intravitreal injections of drugs that inhibit the action of vascular endothelial growth factor (VEGF) lead to gains in vision, but can be expensive and need to be repeated frequently. In addition to VEGF-mediated breakdown of the blood-retinal barrier, recent evidence suggests that inflammation plays an important role in the development of DME. Recognizing this, physicians have injected steroids into the vitreous and developers have created sustained release implants. Intravitreal injections of triamcinolone acetonide lead to rapid resolution of macular edema and significant short-term improvements in visual acuity, but unfortunately, visual acuities diminish when treatment is continued through 2 years. However, intravitreal triamcinolone remains an attractive treatment option for eyes that are pseudophakic, scheduled to undergo catar...Continue Reading

References

Nov 1, 1989·Diabetes/metabolism Reviews·R KleinS E Moss
Jan 1, 1985·Retina·H R McDonald, H Schatz
Aug 1, 1974·Archives of Ophthalmology·R O Graham, G A Peyman
Sep 1, 1971·Experimental Eye Research·I Fatt, K Shantinath
Jan 1, 1980·American Journal of Ophthalmology·Y TanoR Machemer
Jan 1, 1984·Ophthalmology·R KleinS E Moss
Jun 1, 1981·American Journal of Ophthalmology·B W McCuenR Machemer
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 1, 1993·American Journal of Ophthalmology·M S GottfredsdóttirI Gíslason
Mar 1, 1996·The British Journal of Ophthalmology·A HarrisB J Martin
Oct 7, 1997·Clinical and Experimental Pharmacology & Physiology·V A AlderP K Yu
Jan 10, 1998·Hawaii Medical Journal·J H Drouilhet
Sep 15, 1999·Proceedings of the National Academy of Sciences of the United States of America·K MiyamotoA P Adamis
Jan 6, 2001·The American Journal of Pathology·A M JoussenA P Adamis
Sep 1, 2001·American Journal of Ophthalmology·J B Jonas, A Söfker
Nov 1, 1995·Australian and New Zealand Journal of Ophthalmology·P L PenfoldF A Billson
May 3, 2002·Ophthalmology·Adam MartidisCaroline Baumal
Jan 1, 2003·Survey of Ophthalmology·Thomas W GardnerSteven W Levison
Jan 14, 2003·Archives of Ophthalmology·Jost B JonasRobert F Degenring
Sep 19, 2003·Neurologic Clinics·Gregory R Jackson, Cynthia Owsley
Jul 4, 1964·Lancet·E D POWELL, R A FIELD
Dec 4, 2003·Diabetes/metabolism Research and Reviews·Ruth B CaldwellR William Caldwell
Jan 2, 2004·The New England Journal of Medicine·Robert N Frank
Jan 28, 2004·Investigative Ophthalmology & Visual Science·Quan Dong NguyenPeter A Campochiaro
Feb 27, 2004·Investigative Ophthalmology & Visual Science·Heather A Hancock, Timothy W Kraft
Jul 3, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Antonia M JoussenAnthony P Adamis
Nov 9, 2004·American Journal of Ophthalmology·Lindsay M SmithenRichard F Spaide

❮ Previous
Next ❯

Citations

Jan 22, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Philippe DaullJean-Sébastien Garrigue
May 4, 2013·Investigative Ophthalmology & Visual Science·Jason M KeilDavid A Antonetti
Sep 24, 2015·Current Diabetes Reports·Alejandra DaruichFrancine Behar-Cohen
Feb 11, 2015·Cell Biochemistry and Biophysics·Peipei Zhang, Zhanyu Zhou
Nov 30, 2013·Mediators of Inflammation·Snježana KaštelanSpomenka Ljubić
Oct 27, 2016·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Anna BongDavid C Mansfield
Feb 26, 2016·The British Journal of Ophthalmology·J Fernando ArevaloUNKNOWN Pan-American Collaborative Retina Study Group (PACORES)
May 18, 2019·European Journal of Ophthalmology·Adrian Hernández MartínezCarmen-Victoria Almeida-González
Jun 15, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Viviana GuadagniEnrica Strettoi
Sep 2, 2020·Investigative Ophthalmology & Visual Science·Rebekah RobinsonShruti Sharma
Mar 10, 2016·European Journal of Ophthalmology·José F CostaJoão Figueira
Oct 28, 2019·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Mehmet Hakan OzdemirArif Koytak
Oct 8, 2018·Journal of Molecular Neuroscience : MN·Harshini Chakravarthy, Vasudharani Devanathan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here